Öz
Psikotik bozukluğu olan hastalarda oral antipsikotiklere uyum sorunları sık görülür. Uyum yönetimini desteklemek için uzun etkili enjekte edilebilir antipsikotiklerin kullanılması önerilmiştir. Bu çalışmada paliperidon palmitat 3 aylık formülasyon (PP3A) kullanan hastaların incelenmesi amaçlandı. Çalışmaya 21 hasta (8 kadın ve 13 erkek) dahil edildi. Ortalama yaş 40,90±10,98 yıl, hastalık başlangıç yaşı 18,47±3,64 yıl, paliperidon palmitat 1 aylık formülasyon kullanım süresi 12,38±14,68 ay, PP3A kullanım süresi 4,66±1,85 ay idi. Yirmi hasta şizofreni tanılıyken, bir erkek hasta şizoaffektif bozukluk tanılıydı. PP3A uzun süreli sürekli ilaç kullanımı ve takibi gerektirmediğinden uyum sorunu olan hastalarda kullanımı önemli faydalar sağlamaktadır.
Anahtar Kelimeler
Paliperidon palmitat üç aylık uzun etkili enjeksiyon hasta uyumu şizofreni şizoaffektif bozukluk
Kaynakça
- Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180. DOI: 10.2147/PPA.S53795.
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association. 5th ed. Arlington, United States. American Psychiatric Publishing, 2013.
- Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: A review in schizophrenia. Drugs. 2016;76(16):1559-1566. DOI: 10.1007/s40265-016-0645-5.
- Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia. Value Health Reg Issues. 2013;2(2):181-188. DOI: 10.1016/j.vhri.2013.06.008.
- Debaveye S, De Smedt D, Heirman B, Kavanagh S, Dewulf J. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. BMC Health Serv Res. 2019;19(1):393. DOI: 10.1186/s12913-019-4247-2.
- Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251. DOI: 10.1093/ijnp/pyab071.
Öz
Adherence problems to oral antipsychotics are common in patients with psychotic disorders. The use of long-acting injectable antipsychotics has been suggested to support adherence management. This study aimed to examine the patients who used paliperidone palmitate 3-month formulation (PP3M). Twenty-one patients (8 females and 13 males) were included in the study. The mean age was 40.90±10.98 years, the age of disorder onset was 18.47±3.64 years, the duration of paliperidone palmitate once-monthly formulation use was 12.38±14.68 months, the duration of PP3M use was 4.66±1.85 months. While 20 patients were diagnosed with schizophrenia, 1 male patient was diagnosed with schizoaffective disorder. Since PP3M does not require long-term continuous drug use and follow-up, its use in patients with adherence problems provides significant benefits.
Anahtar Kelimeler
Paliperidone palmitate three-month long-acting injection patient compliance schizophrenia schizoaffective disorder
Kaynakça
- Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180. DOI: 10.2147/PPA.S53795.
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association. 5th ed. Arlington, United States. American Psychiatric Publishing, 2013.
- Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: A review in schizophrenia. Drugs. 2016;76(16):1559-1566. DOI: 10.1007/s40265-016-0645-5.
- Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia. Value Health Reg Issues. 2013;2(2):181-188. DOI: 10.1016/j.vhri.2013.06.008.
- Debaveye S, De Smedt D, Heirman B, Kavanagh S, Dewulf J. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. BMC Health Serv Res. 2019;19(1):393. DOI: 10.1186/s12913-019-4247-2.
- Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251. DOI: 10.1093/ijnp/pyab071.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Psikiyatri |
| Bölüm | Kısa Makale |
| Yazarlar | |
| Erken Görünüm Tarihi | 22 Haziran 2023 |
| Yayımlanma Tarihi | 22 Haziran 2023 |
| Gönderilme Tarihi | 17 Nisan 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 1 Sayı: 2 |
